| 1 Global state: 1. clinical improvement (as defined by each study) |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.1 medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
1.42 [0.52, 3.87] |
| 2 Leaving the study early: 1. any reason |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 2.1 medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
0.45 [0.30, 0.67] |
| 3 Leaving the study early: 2. severe adverse effects |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 3.1 medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
2.85 [0.79, 10.24] |
| 4 Leaving the study early: 3. due to relapse or worsening |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 4.1 medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
0.28 [0.17, 0.48] |
| 5 Extrapyramidal adverse effects: 1. akathisia |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 5.1 short/medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
18.50 [4.58, 74.80] |
| 6 Extrapyramidal adverse effects: 2. Parkinsonism |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 6.1 short/medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
3.13 [1.94, 5.03] |
| 7 Extrapyramidal adverse effects: 3. dystonia |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 7.1 short/medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
2.50 [1.31, 4.76] |
| 8 Other adverse effects: 1. specific |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 8.1 decreased appetite ‐ short/medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
0.58 [0.35, 0.97] |
| 8.2 dizziness/faintness ‐ short/medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
12.34 [0.70, 216.49] |
| 8.3 drowsiness ‐ short/medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
2.21 [0.88, 5.56] |
| 8.4 fainting ‐ short/medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
1.90 [0.17, 20.63] |
| 8.5 hypotension ‐ short/medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
1.02 [0.51, 2.01] |
| 8.6 insomnia ‐ short/medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
1.16 [0.50, 2.69] |
| 8.7 nausea/ vomiting ‐ short/medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
0.68 [0.22, 2.07] |
| 8.8 photosensitivity ‐ short/medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
1.26 [0.29, 5.53] |
| 8.9 seizures ‐ short/medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
0.95 [0.06, 14.98] |
| 8.10 skin rashes ‐ short/medium term |
1 |
228 |
Risk Ratio (M‐H, Random, 95% CI) |
0.63 [0.11, 3.71] |
